The FDA has cleared Intuitive Surgical's da Vinci 5 robotic system for select complex cardiac procedures, a move that could reshape the landscape of minimally invasive heart surgery and open a significant new market for the industry leader.
The FDA has cleared Intuitive Surgical's latest robotic system for use in certain heart surgeries, marking a strategic expansion into one of healthcare's largest and most complex service lines and potentially reshaping hospital capital planning for robotics.
Morgan Stanley and Evercore ISI reaffirm bullish ratings on iRhythm, citing strong Q4 preliminary results and growth potential from its next-gen cardiac monitoring technology.
Medtronic secures a key European regulatory nod for its latest pulsed field ablation catheter while deepening its collaboration with Mindray, signaling a strategic push into high-growth areas of cardiac care and ambulatory surgery.
Medtronic's expanded partnership with Mindray integrates its monitoring technologies into ASC-focused platforms, a strategic move to embed itself in a high-growth segment while analysts debate its impact on the broader investment thesis.
While fully autonomous robotic surgeons remain on the horizon, the foundational technology and data ecosystems being built today are setting the stage for a transformative shift. Two industry giants, Intuitive Surgical and Medtronic, offer investors distinct pathways to capitalize on this evolving landscape.
President Luiz Inácio Lula da Silva, 80, was discharged from a Brasília eye hospital on Friday after a successful cataract operation. The veteran leftist leader is recovering at a presidential retreat and is scheduled to return to work on Monday, amid a busy domestic and international agenda.
Brazilian President Luiz Inácio Lula da Silva was released from a São Paulo hospital Friday following a planned cataract procedure on his left eye, with his office confirming a swift return to official duties next week.
A significant reset in analyst price targets for iRhythm Holdings (IRTC) is prompting investors to reassess the cardiac monitoring firm's risk-reward profile. This shift reflects evolving views on reimbursement headwinds, competitive pressures, and long-term growth catalysts in the digital health sector.
Brooke Day died after her backpack became entangled in a gondola lift at Tsugaike Mountain Resort, leading to a fatal cardiac arrest, highlighting rare but critical safety concerns.
Cardiac monitoring specialist iRhythm has finalized a significant corporate restructuring, creating a new parent company to serve as its publicly listed entity on Nasdaq. The move is seen as a strategic step to streamline governance and provide operational flexibility as the company expands its AI-driven health platform.
U.S. District Judge Robert W. Pratt, who served Iowa's Southern District for over 26 years, passed away Wednesday following cardiac arrest. His tenure was marked by significant legal decisions, civic engagement, and a notable public rebuke of former President Donald Trump.
Amid a steep 60% annual share price decline, investment firm Chicago Capital has significantly reduced its position in PROCEPT BioRobotics, a developer of robotic systems for urological surgery, signaling a portfolio risk reassessment.
STAAR Surgical's stock fell sharply after the ophthalmic device maker announced the appointment of interim co-CEOs, fueling investor uncertainty following the CEO's recent departure and a failed takeover attempt.
A Barcelona hospital has completed a groundbreaking facial transplant, the first of its kind globally where the donor offered her face as part of an assisted dying process. The recipient, who lost facial function to a severe infection, is now recovering well.
A suspected human smuggler with a prior conviction was shot by federal agents near the Arizona-Mexico border after allegedly firing at a CBP helicopter and agents during a foot pursuit, according to law enforcement officials.
Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.
Despite a recent 4.7% stock decline, Edwards Lifesciences (NYSE: EW) boasts a robust 13% Return on Equity, outperforming its industry. Yet, its modest 4.6% five-year growth rate raises questions about future potential and market valuation.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
The S&P 500 is home to market leaders, but not all its constituents are created equal. We examine one company navigating challenges and two others positioned for potential growth, providing context on their valuations and market positions.
